Thrombotic microangiopathy during carfilzomib use: case series in Singapore - Summary - MDSpire

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

  • By

  • Y Chen

  • M Ooi

  • S F Lim

  • A Lin

  • J Lee

  • C Nagarajan

  • C Phipps

  • Y S Lee

  • N F Grigoropoulos

  • Z Lao

  • S Surendran

  • E M Teh

  • Y T Goh

  • W J Chng

  • S K Gopalakrishnan

  • July 29, 2016

  • 0 min

Share

Objective:

To report cases of thrombotic microangiopathy (TMA) associated with carfilzomib treatment in patients with multiple myeloma in Singapore.

Key Findings:
  • Include brief patient demographics for better understanding.
Interpretation:

Highlight the clinical implications of the findings more explicitly.

Limitations:
  • Mention potential biases in case selection.
Conclusion:

Reiterate the importance of monitoring TMA in a broader clinical context.

Original Source(s)

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

  • by Y Chen, M Ooi, S F Lim, A Lin, J Lee, C Nagarajan, C Phipps, Y S Lee, N F Grigoropoulos, Z Lao, S Surendran, E M Teh, Y T Goh, W J Chng, S K Gopalakrishnan

  • July 29, 2016

Related Content

An ASCO preview: What to watch for at cancer research’s big meeting

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside